文献速递妇科

低剂量环磷酰胺联合尼达尼布治疗复发性卵巢癌的II期随机安慰剂对照试验

A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer.
PubMed 文献 · Gynecol Oncol · 2020-10-16

该II期随机安慰剂对照试验纳入117例复发性卵巢癌、输卵管癌或原发性腹膜癌患者,随机接受口服环磷酰胺100mg每日一次联合尼达尼布或安慰剂。主要终点总生存期在两组间无显著差异(中位6.8 vs 6.4个月,HR 1.08,95%CI 0.72-1.62,P=0.72)。尼达尼布未改善结局,但23%患者口服环磷酰胺≥6个月。

要点

  • 尼达尼布联合口服环磷酰胺未改善复发性卵巢癌患者的总生存期。
  • 6个月无进展生存率两组分别为29.6%和22.8%,差异无统计学意义(P=0.57)。
  • 既往接受过贝伐珠单抗治疗的患者治疗时间减少52天(P<0.01)。

核心结论

  • 在复发性卵巢癌患者中,尼达尼布联合口服环磷酰胺相比安慰剂联合环磷酰胺未改善总生存期。

研究设计与样本

  • II期随机、安慰剂对照试验,纳入117例复发性卵巢癌、输卵管癌或原发性腹膜癌患者,随机1:1接受口服环磷酰胺100mg每日一次联合尼达尼布或安慰剂。

主要发现

  • 中位总生存期尼达尼布组6.8个月 vs 安慰剂组6.4个月(HR 1.08;95%CI 0.72-1.62;P=0.72)。
  • 6个月无进展生存率尼达尼布组29.6% vs 安慰剂组22.8%(P=0.57)。
  • 3/4级不良事件发生率尼达尼布组64% vs 安慰剂组54%(P=0.28)。
  • 最常见3/4级毒性包括淋巴细胞减少(18.6% vs 16.4%)、腹泻(13.6% vs 0%)、中性粒细胞减少(11.9% vs 0%)、乏力(10.2% vs 9.1%)和呕吐(10.2% vs 7.3%)。
  • 既往接受贝伐珠单抗治疗的患者治疗时间减少52天(P<0.01),26例(23%)患者口服环磷酰胺≥6个月,两组生活质量无差异。

关键数值与推荐

  • 口服环磷酰胺剂量为100mg每日一次。
  • 主要终点为总生存期,次要终点包括无进展生存期、缓解率、毒性和生活质量。

临床怎么用

  • 对于复发性卵巢癌,不推荐在口服环磷酰胺基础上加用尼达尼布用于改善生存。
  • 口服环磷酰胺单药可作为部分复发性卵巢癌患者的治疗选择,但需注意约23%患者可维持治疗≥6个月。

局限性

  • 样本量较小(117例随机),为II期试验。
  • 23%患者口服环磷酰胺≥6个月,可能反映更多惰性疾病患者或环磷酰胺剂量较高,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigated the safety and efficacy of a combination of the oral tyrosine kinase inhibitor, nintedanib (BIBF 1120) with oral cyclophosphamide in patients with relapsed ovarian cancer. PATIENTS AND METHODS: Patients with relapsed ovarian, fallopian tube or primary peritoneal cancer received oral cyclophosphamide (100 mg o.d.) and were randomised (1,1) to also have either oral nintedanib or placebo. The primary endpoint was overall survival (OS). Secondary endpoints included progression free survival (PFS), response rate, toxicity, and quality of life. RESULTS: 117 patients were randomised, 3 did not start trial treatment, median age 64 years. Forty-five (39%) had received ≥5 lines chemotherapy. 30% had received prior bevacizumab. The median OS was 6.8 (nintedanib) versus 6.4 (placebo) months (hazard ratio 1.08; 95% confidence interval 0.72-1.62; P = 0.72). The 6-month PFS rate was 29.6% versus 22.8% (P = 0.57). Grade 3/4 adverse events occurred in 64% (nintedanib) versus 54% (placebo) of patients (P = 0.28); the most frequent G3/4 toxicities were lymphopenia (18.6% nintedanib versus 16.4% placebo), diarrhoea (13.6% versus 0%), neutropenia (11.9% versus 0%), fatigue (10.2% versus 9.1%), and vomiting (10.2% versus 7.3%). Patients who had received prior bevacizumab treatment had 52 days less time on treatment (P < 0.01). 26 patients (23%) took oral cyclophosphamide for ≥6 months. There were no differences in quality of life between treatment arms. CONCLUSIONS: This is the largest reported cohort of patients with relapsed ovarian cancer treated with oral cyclophosphamide. Nintedanib did not improve outcomes when added to oral cyclophosphamide. Although not significant, more patients than expected remained on treatment for ≥6 months. This may reflect a higher proportion of patients with more indolent disease or the higher dose of cyclophosphamide used. CLINICAL TRIAL REGISTRATION: Clinicaltrials.govNCT01610869.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hall MR, Dehbi HM, Banerjee S, et al. A phase II randomised, placebo-controlled trial of low dose (metronomic) cyclophosphamide and nintedanib (BIBF1120) in advanced ovarian, fallopian tube or primary peritoneal cancer. Gynecol Oncol. 2020. PMID: 33077258. doi:10.1016/j.ygyno.2020.09.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。